Ann: Fourfold Delivery Improvement in a New Lead Candidate, page-17

I do agree with the sentiment of some of the above comments. But remember, this was never goinjg to be ab easy or fast ride. eACH YEAR they are progressing in various ways and now the big differences might add up to a market rerate which could stun most.

I am thinking the following need the market to sit up and take notice( not in any order in partic)

1/Tribe and mates can keep company going

2/rapid screening of BILLIONS of Phylomers has just commenced and 2 candidates 80x better than TAT have been found from 10% of the library, so there will be more discoveries yet..

3/they still have the holy grail up their sleeve and will get some market attention when that starts clinical trials ( not that long away if you think about the life of the company)

4/various negotiations going on but all pre signature so... we are mushrooms

5/ Rohan can speak the talk better than previous CEO's

6/the whole package is on a few radars and might become a take over target but the registry is tight enough to make that scenario difficult ie at the right price.. ( ? 500m at the moment)

7/ the platform deals are close too....

That all adds up to why we see no selling in my view.